Mersana Therapeutics, Inc(NASDAQ:MRSN) 
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development of antibody drug conjugates (ADC) for cancer patients with unmet need. The company develops XMT-1536, a Dolaflexin ADC targeting NaPi2b that is in Phase I clinical trial for the treatment of patients w...
Website: http://www.mersana.com
Founded: 2001
Full Time Employees: 83
Sector: Healthcare
Industry: Biotechnology
The information provided in this report is taken from www.sec.gov. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Day
Week
Month
Date 2025-04-04
P
O 7.75
H 8.25
L 7.25
C 7.50
V 2,347,413
10EMA 7.50
20EMA 7.50
60EMA 7.50
120EMA 7.50
250EMA 7.50